Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 6 Similar Profiles
Melanoma Medicine & Life Sciences
Merkel Cell Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Skin Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Chemoprevention Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2005 2021

Research Output 2004 2018

  • 4804 Citations
  • 17 h-Index
  • 31 Article
  • 6 Letter
  • 5 Review article
  • 2 Comment/debate
5 Citations

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Lin, H., Wei, S., Hurt, E. M., Green, M. D., Zhao, L., Vatan, L., Szeliga, W., Herbst, R., Harms, P. W., Fecher, L. A., Vats, P., Chinnaiyan, A. M., Lao, C. D., Lawrence, T. S., Wicha, M., Hamanishi, J., Mandai, M., Kryczek, I. & Zou, W. Feb 1 2018 In : Journal of Clinical Investigation. 128, 2, p. 805-815 11 p.

Research output: Contribution to journalArticle

Dendritic Cells
Macrophages
Programmed Cell Death 1 Receptor
Neoplasms
Death Domain Receptors
13 Citations

Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Larkin, J. , Minor, D. , D'Angelo, S. , Neyns, B. , Smylie, M. , Miller, W. H. , Gutzmer, R. , Linette, G. , Chmielowski, B. , Lao, C. D. , Lorigan, P. , Grossmann, K. , Hassel, J. C. , Sznol, M. , Daud, A. , Sosman, J. , Khushalani, N. , Schadendorf, D. , Hoeller, C. , Walker, D. & 3 others Kong, G., Horak, C. & Weber, J. Feb 1 2018 In : Journal of Clinical Oncology. 36, 4, p. 383-390 8 p.

Research output: Contribution to journalArticle

Melanoma
Research Personnel
Drug Therapy
Survival
nivolumab
4 Citations

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)

Kalinsky, K., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., Margolin, K. A., Leitao, M. M., Tarhini, A. A., Koon, H. B., Pecora, A. L., Jaslowski, A. J., Cohen, G. I., Kuzel, T. M., Lao, C. D. & Kirkwood, J. M. Jul 15 2017 In : Cancer. 123, 14, p. 2688-2697 10 p.

Research output: Contribution to journalArticle

Melanoma
Extremities
Research
Solar System
Neoplasms
21 Citations

Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials

Schadendorf, D., Wolchok, J. D., Stephen Hodi, F., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Lance Cowey, C., Lao, C. D., Chesney, J., Robert, C., Grossmann, K., McDermott, D., Walker, D., Bhore, R., Larkin, J. & Postow, M. A. Dec 1 2017 In : Journal of Clinical Oncology. 35, 34, p. 3807-3814 8 p.

Research output: Contribution to journalArticle

Melanoma
Safety
Therapeutics
ipilimumab
nivolumab
Merkel Cell Carcinoma
Clinical Trials
Publications
Neoplasms
nivolumab